Details

Autor(en) / Beteiligte

• Ding, Xiao
• Cui, Jiuwei

Titel

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer

Ist Teil von

• Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14276-e14276

Erscheinungsjahr

2019

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Abstract only e14276 Background: Adjuvant chemotherapy has been established as a standard for patients with early stage NSCLC after complete tumor resection, but the 5-year survival rate can only increase by about 5%. Given its high morbidity and mortality, new biomarkers are needed to predict clinical response and prognosis of resected NSCLC. The expression of MHC-I, PD-L1 and CD8 + TILs were detected in this study to investigate the potential prognostic markers in patients with early stage NSCLC. Methods: Tissue of 125 patients with surgically resected NSCLC (stage I-III) were obtained from the First Hospital of Jilin Universtiy. MHC-I, PD-L1 and CD8 + TILs were detected with immunohistochemistry. The association between their expression levels and patients’ prognosis was analyzed. Results: MHC-I was down-expressed, and PD-L1 was up-expressed in NSCLC tissues compared with the para-cancer tissues. CD8 + TILs could be seen in tumor stroma and nest. PFS and OS was poorer in MHC-I low group compared with MHC-I high group (P < 0.05). PFS and OS in PD-L1 − group tended to be longer than the PD-L1 + group, but the difference was not significant (P > 0.05). For CD8 + TILs, PFS and OS of the CD8 inflamed group were longer than the CD8 non-inflamed group (P < 0.05). With multivariate analysis, we found that MHC-I and CD8 + TILs might be independent prognostic factors of NSCLC (P < 0.05). Based on the PD-L1 and CD8 + TILs expression, we divided the patients into four subgroups: PD-L1 + /CD8 inflamed , PD-L1 + /CD8 non-inflamed , PD-L1 − /CD8 inflamed , and PD-L1 − /CD8 non-inflamed . Statistical differences were achieved both in PFS and OS (P < 0.05). PFS and OS of the PD-L1 + /CD8 inflamed and PD-L1 − /CD8 inflamed group were longer than the other two groups. Patients with PD-L1 + /CD8 non-inflamed experienced the worst PFS and OS. Besides, we divided the patients into four subgroups according to their MHC-I and CD8 + TILs expression conditions: MHC-I high /CD8 inflamed , MHC-I high /CD8 non-inflamed , MHC-I low /CD8 inflamed , and MHC-I low /CD8 non-inflamed . Statistical differences were achieved both in PFS and OS of these subgroups (P < 0.05). PFS and OS of the MHC-I high /CD8 inflamed group were longer than the other three groups. Patients in MHC-I low /CD8 non-inflamed group experienced the worst PFS and OS. Conclusions: It was reported for the first time that the combination of PD-L1 and CD8 + TILs, MHC-I and CD8 + TILs suggested impressive prognostic values in early stage NSCLC in this study. The comprehensive analysis of immune indicators may provide prognostic markers for early stage NSCLC.